DaVita (DVA) drew attention after its stock outperformed both the broader market and the medical sector, with investors positioning ahead of an upcoming earnings report that is expected to show increased EPS and revenue.
See our latest analysis for DaVita.
At a share price of $236.97, DaVita has built strong momentum, with a 30 day share price return of 13.98% and a year to date share price return of 106.94%. The 3 year total shareholder return of 130.56% points to meaningful longer term gains.
If DaVita's run has you thinking about where capital could work next, this is a good moment to scan for other healthcare related opportunities through 39 healthcare AI stocks
After DaVita's sharp move, and with the stock trading above the average analyst target and some intrinsic estimates, the real tension is clear: is the current price already rich, or is the fair value bar simply higher?
Most Popular Narrative: 22.3% Overvalued
DaVita is trading at $236.97 compared with a widely followed fair value estimate of $193.71, so the current price sits well above that narrative anchor, putting the focus on the assumptions that bridge the gap.
The analysts have a consensus price target of $193.71 for DaVita based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $235.0, and the most bearish reporting a price target of just $145.0.
Want to see what is baked into that fair value for DaVita? The narrative leans heavily on carefully shaped revenue growth, margin lift, and a lower future earnings multiple. The mix of buybacks, discount rate tweaks, and long term profit assumptions is doing more work than it first appears.
Result: Fair Value of $193.71 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still real vulnerability in the DaVita narrative if patient mortality stays elevated or if reimbursement updates continue to lag underlying cost inflation.
Find out about the key risks to this DaVita narrative.
Another View on DaVita's Valuation
The fair value narrative pegs DaVita at $193.71 and frames the current $236.97 share price as 22.3% rich, but the earnings multiple tells a different story. On a P/E of 20.1x versus a fair ratio of 26.3x, DaVita screens as good value relative to its own fundamentals, peers at 39.9x, and the broader US Healthcare industry at 26x. If the market ever moves closer to that fair ratio, how confident are you in the assumptions behind each approach?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism around DaVita's momentum and concern around its valuation and risk factors, it makes sense to assess the full picture quickly and decide where you stand. To help weigh those trade offs for yourself, take a close look at the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond DaVita?
If DaVita has sharpened your focus, do not stop here. Use the Simply Wall St screener to spot fresh ideas before the crowd catches on.
- Target robust cash generators and disciplined capital allocators by scanning 47 high quality undervalued stocks that combine quality fundamentals with pricing that still looks reasonable.
- Strengthen the defensive side of your portfolio by reviewing 82 resilient stocks with low risk scores with resilience scores designed to help you avoid unpleasant surprises.
- Get ahead of the market by tracking screener containing 20 high quality undiscovered gems that pair solid fundamentals with relatively low investor attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com